Compare TEX & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEX | KYMR |
|---|---|---|
| Founded | 1933 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 7.1B |
| IPO Year | 1994 | 2020 |
| Metric | TEX | KYMR |
|---|---|---|
| Price | $57.82 | $78.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 26 |
| Target Price | $68.80 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 1.1M | 440.4K |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,421,000,000.00 | $39,211,000.00 |
| Revenue This Year | $47.67 | $10.61 |
| Revenue Next Year | $6.66 | $8.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.73 | N/A |
| 52 Week Low | $41.70 | $28.06 |
| 52 Week High | $71.50 | $103.00 |
| Indicator | TEX | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 42.42 | 40.35 |
| Support Level | $54.46 | $77.71 |
| Resistance Level | $58.66 | $89.80 |
| Average True Range (ATR) | 2.67 | 3.23 |
| MACD | -0.66 | -0.58 |
| Stochastic Oscillator | 28.45 | 14.38 |
Terex is a global manufacturer of aerial work platforms, materials processing equipment, and specialty equipment for the waste, recycling, and utility industries. Its current composition is a result of numerous acquisitions over several decades to focus on a smaller group of light construction and other vocational equipment, having divested a handful of underperforming businesses, particularly in cranes and other lifting equipment. These remaining segments see heavy demand in nonresidential construction (aerial work platforms—40% sales), aggregates/mining (materials processing—30% sales), environmental, waste/recycling and utilities (environmental solutions group—30% sales).
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.